Hon Hai Group (鴻海集團) on Saturday denied that Apple Inc had returned 5 million iPhones produced at Hon Hai’s plants in China because of flaws in their appearance or malfunctions.
The China Business Journal quoted an unnamed source at the Foxconn Technology Group (富士康科技集團), Hon Hai’s trade name in China, as saying that the US consumer electronics giant had returned 5 million iPhones on March 15.
The handsets were returned either because they were not functioning well or did not meet Apple’s standards for appearance, the Beijing-based weekly said.
The number of faulty iPhones has reached 8 million units, the report said, citing the Foxconn source.
The report also said it would cost Hon Hai between 1 billion yuan (US$161.8 million) and 1.6 billion yuan to repair the defective handsets.
According to the report, Futaihua Precision Electronics Co (富泰華), a Foxconn subsidiary, has begun producing iPhones, with each of its assembly lines churning out 1,000 to 2,000 units per day.
However, the plant’s yield rate is only 95 percent, the report said.
Hon Hai spokesman Simon Hsing (邢治平) denied the figures mentioned in the report.
However, he said that the company will look into management and product yield rate issues mentioned in the report.
Institutional investors said recently that Apple products now account for more than 50 percent of Hon Hai’s revenues.
Separately, Hon Hai Precision Industry Co (鴻海精密), the world’s largest contract electronics maker and the flagship company of Hon Hai Group, said on Saturday that a deadly earthquake that struck China’s Sichuan Province earlier in the day had not affected the company’s production facilities in the province.
Hon Hai said its staff in the province’s capital, Chengdu, were all safe after the magnitude 6.6 earthquake.
After checks at its plants in Chengdu, Hon Hai said there has been no damage to the facilities, and operations remain normal.
JPMorgan Chase & Co chief executive officer Jamie Dimon on Tuesday quipped that his company is likely to outlast the Chinese Communist Party (CCP), while reiterating the bank’s commitment to the country in wide-ranging comments that also touched on Taiwan, free speech and former US president Donald Trump. “We hope to be there [in China] for a long time,” Dimon told a panel discussion at the Boston College Chief Executives Club. Relaying a “joke” he made during a recent visit to Hong Kong, he said “The communist party is celebrating its 100th year. So is JPMorgan. And I’ll make you a
The Kaohsiung City Government yesterday said it would impose a property hoarding tax as it is seeking to contain speculation in the real-estate market, calling recent price increases “abnormal.” The announcement came in support of the Ministry of Finance’s call for local governments to levy a high tax rate on people with more than one property. Ministry officials on Tuesday discussed strategies to rein in speculation with the nation’s six special municipalities, as well as the Hsinchu city and county governments. About 84,000 out of 1.06 million housing units in Kaohsiung are not residential property, the city government said in a
BOOST EXPECTED: Higher market prices would offset effects of the industry’s transition to more climate-friendly production methods, a company official said China Steel Corp (CSC, 中鋼) expects steel demand to increase on the back of governments around the world subsidizing infrastructure construction amid a stabilizing COVID-19 pandemic, CSC chairman Wong Chao-tung (翁朝棟) told an investors’ meeting yesterday. “After getting through the hard times, I foresee at least one year, very possibly two years, of strong steel market,” Wong said. Calling a dip in steel prices a “short respite for the market,” Wong said that it would likely bounce back early next year on the back of mild winter temperatures around the world allowing construction activity. Despite COVID-19 spikes in some regions and increased
PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12. Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12. PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack. PharmaEssentia is preparing to make Besremi available in the US in the